Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
Rubraca’s FDA approval before chemo in BRCA-mutated prostate cancer could reshape precision treatment. See what this changes for mCRPC strategy.
How Pictor’s ViraScreen-Core is reshaping clinical lab workflows for infectious disease testing
Explore how Pictor’s ViraScreen-Core multiplex antibody assay aligns with evolving CDC hepatitis B testing guidance and what it means for clinical diagnostics.
Meta-Flux and Mercury Bio team up to target intracellular CNS pathways with precision
Mercury Bio Inc., a biotechnology company focused on large-molecule therapeutics, has announced a strategic collaboration with Meta-Flux, a disease simulation company that leverages artificial intelligence, to advance drug discovery programs for Parkinson’s disease and Alzheimer’s disease. The partnership combines Mercury Bio’s proprietary yeast extracellular vesicle (yEV) delivery technology with Meta-Flux’s disease-scale computational modeling platform, with […]
Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can
Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound) […]
Wasatch BioLabs, Agilent to scale native-read targeted sequencing for precision multi-omics
Wasatch BioLabs has announced a co-marketing agreement with Agilent Technologies to expand access to its Direct Targeted Methylation Sequencing (dTMS) platform. The partnership integrates Agilent’s SureSelect and Avida enrichment chemistries with Wasatch BioLabs’ Oxford Nanopore-based native-read workflow, aiming to streamline high-throughput targeted sequencing for research use only (RUO) and translational settings. The announcement marks a […]
Why Boehringer’s $10bn U.S. investment and TrumpRx deal may reshape pharma cost dynamics
Boehringer Ingelheim’s $10B U.S. investment and TrumpRx.gov deal may redefine drug pricing and supply chains. Find out what this changes for pharma now.
Hardy Diagnostics bets on chemiluminescent testing with NEMIS’s N-Light platform
Hardy Diagnostics has announced an exclusive partnership with NEMIS Technologies to introduce the N-Light rapid pathogen detection platform across North America. The move brings chemiluminescent-based hygiene monitoring—already validated in several European food manufacturing segments—into the U.S. market at a time when regulatory focus on proactive food safety and decentralized diagnostics is accelerating. The announcement positions […]
Meiji Seika Pharma’s alliance with MBC BioLabs signals a bold shift in global R&D sourcing strategy
Meiji Seika Pharma Co., Ltd. has announced a strategic partnership with MBC BioLabs, a leading biotech incubator based in California’s San Francisco Bay Area, to expand its global drug discovery initiatives. The Tokyo-headquartered pharmaceutical firm aims to deepen its open innovation approach by tapping into early-stage biotech talent in the United States, with a focus […]
PADCEV plus Keytruda meets survival endpoints in cisplatin-eligible bladder cancer patients
Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival […]
Indivior’s SUBLOCADE shows stronger outcomes in high-frequency fentanyl users: What this changes for opioid use disorder treatment in 2026
Indivior’s new data shows SUBLOCADE 300 mg may improve outcomes in fentanyl users with OUD. Find out what this means for future treatment.